Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Core Insights - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [4] - The CEO, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45 Annual Growth Conference from August 12-14, 2025 [1][2] - The company aims to introduce novel T cell therapies to the market and improve patient outcomes while preserving financial resources and focusing on operational excellence [4] Event Details - The fireside chat is scheduled for August 12, 2025, from 12:30 to 12:55 p.m. EDT at the InterContinental Boston Hotel [2] - During the conference, Dr. Vera and the management team will hold one-on-one meetings with registered investors to discuss the Multi-Antigen Recognizing (MAR) T cell platform and clinical developments [2] - Investors can access the event online through the company's Investor Relations website [3] Company Background - Marker Therapeutics was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its MAR-T cell products are well tolerated and show durable clinical responses [4] - The company benefits from non-dilutive funding from U.S. state and federal agencies supporting cancer research, which strengthens its unique T cell platform [4]